Skip to content

Modified Shenqi Dihuang Decoction Combined with Androgen Deprivation Therapy for Hormone-Sensitive Prostate Cancer: A Randomized Controlled Clinical Trial

Modified Shenqi Dihuang Decoction Combined with Androgen Deprivation Therapy for Hormone-Sensitive Prostate Cancer: A Randomized Controlled Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001093
Enrollment
Unknown
Registered
2025-06-02
Start date
2023-03-01
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Control Group:Standard Androgen Deprivation Therapy with Conventional Symptomatic Management
Experimental Group:Standard Androgen Deprivation Therapy Combined with Modified Shenqi Dihuang Decoction (with Individualized Modifications) for Hormone-Sensitive Prostate Cancer

Sponsors

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Locally Advanced Prostate Cancer: Prostate cancer with invasion into bladder rectum pelvis external sphincter levator ani muscle or internal obturator muscle or pelvic lymph node metastasis distal to the aortic bifurcation with maximum metastatic lymph node diameter =3 cm; 2) Low Tumor Burden Metastatic Prostate Cancer: =3 bone metastases without extra-axial skeletal metastases (e.g. pelvis vertebrae) and absence of visceral metastases; 3) Inclusion Criteria: Aged 50-80 years life expectancy >12 months no prior radical prostatectomy radiotherapy or chemotherapy for prostate cancer; 4) Ethical Requirements: Voluntary participation with signed informed consent and willingness to comply with treatment protocols.

Exclusion criteria

Exclusion criteria: 1) Critically ill patients with life expectancy <6 months; 2) Hypersensitivity to Modified Shenqi Dihuang Decoction; 3) Concomitant primary malignancy other than prostate cancer; 4) Severe primary diseases of cardiovascular hepatic renal or hematopoietic systems; 5) Psychiatric disorders or Alzheimer's disease with inability to cooperate with treatment; 6) Non-adherence to clinical research protocol requirements; 7) Subjects currently enrolled in other drug clinical trials.

Design outcomes

Primary

MeasureTime frame
6- and 12-month Non-Progression Rate;

Secondary

MeasureTime frame
Progression-Free Survival (PFS) and Overall Survival (OS);NRS;ECOG;

Countries

China

Contacts

Public ContactXu dongliang

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Dr_xudongliang@shutccm.edu.cn13918829767

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026